DRAPALIN is the new brand for high-quality medical cannabis on the German market.
With the coming into force of the “Cannabis as Medicine” law on March 10, 2017, the possibilities for prescribing medicinal cannabis products were expanded. As a result, medical cannabis flowers have become reimbursable by the statutory health insurance funds.
After this reform of the narcotics law, the founders came up with the idea of establishing a wholesale company for medical cannabis on the German market.
Thus, in December 2017, the founding team consisting of Ilya Garev, Lana Korneva, Anne-Sophie Cavar, Konstantin Lubsky and Ivan Garev launched the company DRAPALIN Pharmaceuticals GmbH based in Munich.
Our team aims to improve the medical cannabis market environment by providing physicians, pharmacists and wholesalers with an extensive logistics network, a quality product that complies with the regulations of the German market, and comprehensive information support through our high service level network.
DRAPALIN aims to become a globally oriented company with a vertically integrated structure that allows us to control the entire life cycle of the product – from cultivation to processing and distribution.
Our goal is to gain a high level of trust in the medical community and promote the well-being of patients in Germany.
Wholesale trading of medicinal products in accordance with Section 52a (1) of the Medicinal Products Act (Arzneimittelgesetz – AMG), issued by the Government of Upper Bavaria:
This permit represents the basic authorization to place medicinal products on the market in the Federal Republic of Germany as a wholesaler. It authorizes the distribution to pharmacies or other wholesalers, but not directly to patients, as this is reserved for pharmacies under German law.DRAPALIN received the wholesale authorization in September 2019.
Certificate of GDP compliance of a wholesaler distributor in accordance with Art. 111 of Directive 2001/83/EC, issued by the Government of Upper Bavaria:
The GDP certificate (“Good Distribution Practice”) certifies that a pharmaceutical wholesaler’s entire distribution chain – including logistics, storage and transport – complies with the quality requirements of the EU-GDP Guide.DRAPLAIN received its GDP certificate in September 2019.
Certificate of GMP compliance of a manufacturer in accordance with Art. 111 (5) of Directive 2001/83/EC, issued by the Government of Upper Bavaria:
The GMP certificate (“Good Manufacturing Practice”) proves that the certified manufacturer complies with the quality standards required for the manufacture of medicinal products. Within the European Union, only medicinal products manufactured in accordance with EU GMP standards may be marketed. DRAPALIN successfully advised and accompanied a Canadian manufacturer of medical cannabis on its way to GMP certification by the Government of Upper Bavaria.
Permit according to § 3 BtMG (German Narcotic Drugs Act), issued by the Federal Institute for Drugs and Medical Devices (BfArM):
An additional narcotics permit is required for the distribution of drugs that are classified as narcotics under German law, such as medical cannabis.DRAPALIN received the narcotics permit in July 2020.
Registration as a distributor of active ingredients in accordance with Section 67 (1) AMG in conjunction with Section 64 (3g) AMG, by the Government of Upper Bavaria:
Wholesalers of active ingredients are required to notify the competent authorities of their activities. This ensures that the circulation of these products can be monitored by the regulatory authorities. In addition, the companies concerned are registered in an official database: